{"id":"https://openalex.org/W2284028653","doi":"https://doi.org/10.1186/s12933-016-0356-y","title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","display_name":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","alternate_titles":[],"publication_year":2016,"publication_date":"2016-02-19","ids":{"openalex":"https://openalex.org/W2284028653","doi":"https://doi.org/10.1186/s12933-016-0356-y","mag":"2284028653","pmid":"https://pubmed.ncbi.nlm.nih.gov/26895767","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4761166"},"language":"en","primary_location":{"id":"doi:10.1186/s12933-016-0356-y","doi":"https://doi.org/10.1186/s12933-016-0356-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12933-016-0356-y","pdf_url":null,"source":{"id":"https://openalex.org/S12095120","display_name":"Cardiovascular Diabetology","issn_l":"1475-2840","issn":["1475-2840"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Diabetology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2284028653"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1186/s12933-016-0356-y","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083911432","display_name":"Christian Sonesson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Christian Sonesson","raw_affiliation_strings":["AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Christian.Sonesson@astrazeneca.com","AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Christian.Sonesson@astrazeneca.com","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Peter A. Johansson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter A. Johansson","raw_affiliation_strings":["AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Peter.A.Johansson@astrazeneca.com","AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Peter.A.Johansson@astrazeneca.com","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031725659","display_name":"EVA K. JOHNSSON","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eva Johnsson","raw_affiliation_strings":["AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Eva.Johnsson@astrazeneca.com","AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Eva.Johnsson@astrazeneca.com","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007149007","display_name":"Ingrid A. M. Gause\u2010Nilsson","orcid":"https://orcid.org/0000-0002-3758-8237","observed_orcids":["https://orcid.org/0000-0002-3758-8237"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ingrid Gause-Nilsson","raw_affiliation_strings":["AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Ingrid.Gause-Nilsson@astrazeneca.com","AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden. Ingrid.Gause-Nilsson@astrazeneca.com","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83, M\u00f6lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5083911432"],"corresponding_institution_ids":["https://openalex.org/I4210143795"],"apc_list":{"value":4290,"currency":"USD","value_usd":4290},"apc_paid":{"value":4290,"currency":"USD","value_usd":4290},"fwci":5.0068,"has_fulltext":true,"cited_by_count":190,"citation_normalized_percentile":{"value":0.97408207,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":100},"biblio":{"volume":"15","issue":"1","first_page":"37","last_page":"37"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":0.9309999942779541},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9139999747276306},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.7509999871253967},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.9950000047683716},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.847000002861023},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.6919999718666077},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.7450000047683716},{"id":"https://openalex.org/keywords/cardiovascular-disease-history","display_name":"cardiovascular disease history","score":0.6909999847412109},{"id":"https://openalex.org/keywords/cardiovascular-risk-factors","display_name":"cardiovascular risk factors","score":0.7039999961853027},{"id":"https://openalex.org/keywords/glucose-lowering-therapy","display_name":"glucose-lowering therapy","score":0.578000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9080770015716553},{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.8280008435249329},{"id":"https://openalex.org/C555175668","wikidata":"https://www.wikidata.org/wiki/Q539690","display_name":"Angiology","level":2,"score":0.6603875756263733},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.645341694355011},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6396408677101135},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5977055430412292},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5313290357589722},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.32720649242401123},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2111939787864685}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051247","descriptor_name":"Sodium-Glucose Transport Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051247","descriptor_name":"Sodium-Glucose Transport Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065840","descriptor_name":"Protective Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1186/s12933-016-0356-y","doi":"https://doi.org/10.1186/s12933-016-0356-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12933-016-0356-y","pdf_url":null,"source":{"id":"https://openalex.org/S12095120","display_name":"Cardiovascular Diabetology","issn_l":"1475-2840","issn":["1475-2840"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Diabetology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4761166","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4761166/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4761166/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovasc Diabetol","raw_type":"Text"},{"id":"pmh:oai:europepmc.org:3730494","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4761166","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:26895767","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26895767","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular diabetology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1186/s12933-016-0356-y","doi":"https://doi.org/10.1186/s12933-016-0356-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12933-016-0356-y","pdf_url":null,"source":{"id":"https://openalex.org/S12095120","display_name":"Cardiovascular Diabetology","issn_l":"1475-2840","issn":["1475-2840"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Diabetology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2284028653.pdf","grobid_xml":"https://content.openalex.org/works/W2284028653.grobid-xml"},"referenced_works_count":66,"referenced_works":["https://openalex.org/W172609984","https://openalex.org/W1517491980","https://openalex.org/W1523363225","https://openalex.org/W1526927233","https://openalex.org/W1953840628","https://openalex.org/W1970736869","https://openalex.org/W1973240292","https://openalex.org/W2001991301","https://openalex.org/W2007221722","https://openalex.org/W2008443217","https://openalex.org/W2010562008","https://openalex.org/W2015191704","https://openalex.org/W2022119612","https://openalex.org/W2027398852","https://openalex.org/W2030192134","https://openalex.org/W2033417941","https://openalex.org/W2054361323","https://openalex.org/W2064130493","https://openalex.org/W2068907080","https://openalex.org/W2069397244","https://openalex.org/W2072040765","https://openalex.org/W2076506641","https://openalex.org/W2076573528","https://openalex.org/W2077636750","https://openalex.org/W2090816085","https://openalex.org/W2091977092","https://openalex.org/W2095682936","https://openalex.org/W2097995302","https://openalex.org/W2101865653","https://openalex.org/W2105892231","https://openalex.org/W2106426335","https://openalex.org/W2110333911","https://openalex.org/W2110660701","https://openalex.org/W2111876001","https://openalex.org/W2114250030","https://openalex.org/W2114276479","https://openalex.org/W2115653936","https://openalex.org/W2115868962","https://openalex.org/W2117505171","https://openalex.org/W2120649968","https://openalex.org/W2122077393","https://openalex.org/W2123984464","https://openalex.org/W2124658554","https://openalex.org/W2126919962","https://openalex.org/W2127833912","https://openalex.org/W2127854619","https://openalex.org/W2139171405","https://openalex.org/W2140887581","https://openalex.org/W2142593697","https://openalex.org/W2142830692","https://openalex.org/W2146264128","https://openalex.org/W2147222003","https://openalex.org/W2148513135","https://openalex.org/W2150855258","https://openalex.org/W2153839551","https://openalex.org/W2158666727","https://openalex.org/W2160088494","https://openalex.org/W2166247199","https://openalex.org/W2172193326","https://openalex.org/W2182718273","https://openalex.org/W2187514862","https://openalex.org/W2208793669","https://openalex.org/W2436309489","https://openalex.org/W2905404013","https://openalex.org/W3098181726","https://openalex.org/W4244540230"],"related_works":["https://openalex.org/W2339689947","https://openalex.org/W2341082036","https://openalex.org/W186471437","https://openalex.org/W4385738165","https://openalex.org/W2317190709","https://openalex.org/W891120635","https://openalex.org/W3094242643","https://openalex.org/W2474731057","https://openalex.org/W2533360279","https://openalex.org/W2326899974"],"abstract_inverted_index":{"BACKGROUND:":[0],"A":[1,120],"pre-specified":[2],"meta-analysis":[3],"of":[4,22,56,60,69,104,226,241,249,257,268,288,300],"cardiovascular":[5],"(CV)":[6],"events":[7,90,251],"from":[8],"21":[9,64],"phase":[10],"2b/3":[11],"dapagliflozin":[12,32,57,159,175,294],"clinical":[13],"trials":[14],"was":[15,264,285],"undertaken":[16],"to":[17,51,134,146],"characterise":[18,52],"the":[19,53,198,206,301,306,309,320],"CV":[20,29,54,70,89,105,108,115,124,192,242,258,314,324],"profile":[21,55],"dapagliflozin.":[23],"This":[24],"showed":[25],"no":[26,265,286],"increase":[27],"in":[28,58,62,126,169,205,221,236,252,270,298],"risk":[30,78,116,125,193,259,267,290,325],"with":[31,34,40,83,94,101,190,223,238,278,293,296,319,328],"compared":[33,123,277,295],"control":[35,183,297],"(placebo":[36],"or":[37,41],"comparator":[38],"treatment)":[39],"without":[42],"background":[43],"glucose-lowering":[44],"therapies.":[45],"The":[46],"analysis":[47,122],"reported":[48],"here":[49],"aimed":[50],"subgroups":[59],"patients":[61,127,166,173,237,271],"these":[63],"studies":[65],"grouped":[66],"by":[67,156],"degree":[68],"risk,":[71,106,243],"based":[72,143],"on":[73,86,144,323],"both":[74,98,204],"baseline":[75],"and":[76,100,113,136,180,194,220,247,255],"in-study":[77],"factors":[79,260,326],"(including":[80],"hypoglycaemic":[81,131,275],"events),":[82],"a":[84,130,150,201,224,274,312],"focus":[85],"major":[87],"adverse":[88],"(MACE).":[91],"METHODS:":[92],"Patients":[93],"type":[95,248],"2":[96],"diabetes,":[97],"overall":[99,207],"different":[102],"levels":[103],"including":[107,244],"disease":[109],"(CVD)":[110],"history,":[111],"age":[112],"other":[114],"factors,":[117],"were":[118,142,167,234],"analysed.":[119],"further":[121,196],"who":[128,138,272,280],"experienced":[129,273],"event":[132,148,276],"prior":[133],"MACE":[135,269,292],"those":[137,222,279],"did":[139,281],"not.":[140,282],"Analyses":[141],"time":[145],"first":[147],"using":[149],"Cox":[151],"proportional":[152],"hazards":[153],"model":[154],"stratified":[155],"study":[157],"comparing":[158],"versus":[160],"control.":[161],"RESULTS:":[162],"In":[163,304],"total,":[164],"9339":[165],"included":[168],"this":[170],"meta-analysis;":[171],"5936":[172],"received":[174,182],"2.5-10":[176],"mg":[177],"(6668":[178],"patient-years)":[179],"3403":[181],"(3882":[184],"patient-years).":[185],"Dapagliflozin":[186],"is":[187,317],"not":[188],"associated":[189,327],"increased":[191,266,289],"results":[195,307],"suggest":[197,308],"potential":[199,310],"for":[200,218,291,311],"beneficial":[202,313],"effect":[203,315],"population":[208],"[Hazard":[209],"Ratio":[210],"(HR)":[211],"0.77;":[212],"95":[213],"%":[214],"CI":[215],"(0.54,":[216],"1.10)":[217],"MACE]":[219],"history":[225,254],"CVD":[227,250],"[HR":[228],"0.80":[229],"(0.53,":[230],"1.22)].":[231],"These":[232],"findings":[233],"consistent":[235,318],"varying":[239],"degrees":[240],"age,":[245],"number":[246,256],"medical":[253],"present.":[261],"Furthermore,":[262],"there":[263],"CONCLUSIONS:":[283],"There":[284],"suggestion":[287],"any":[299],"populations":[302],"investigated.":[303],"addition,":[305],"which":[316],"multifactorial":[321],"benefits":[322],"sodium-glucose":[329],"cotransporter-2":[330],"(SGLT2)":[331],"inhibitors.":[332]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2284028653","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":21},{"year":2019,"cited_by_count":24},{"year":2018,"cited_by_count":38},{"year":2017,"cited_by_count":51},{"year":2016,"cited_by_count":19}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
